Youâre reading a free article with opinions that may differ from The Motley Foolâs Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.
RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partnerâs brokerage products, these are focused on the trading of readily releasable securities.
On a current yield of 5.3%, does AstraZeneca have what it takes to make it into our special report “5 Shares To Retire On“? To find out the names of the five shares, and the reasons behind their inclusion, simply click here to have it delivered free to your inbox.
https://youtu.be/JnGcU8Kc1XM
In this video series, Owain Bennallack take a look at some of the best routes within the FTSE 100 to gain from the growth of emerging markets. Under the spotlight this time is AstraZeneca (LSE: AZN) (NYSE: AZN.US).
